Drug Trial Radar · NCT01569581
A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children
Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,000
Actual
Start
Mar 2012
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangxi Center for Disease Control and Prevention
- First posted
- Apr 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 71 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Enterovirus 71 (EV71), a major pathogen that is responsible for causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Since the late 1990s, a series of large HFMD epidemics caused by EV71 have been reported in the Asia-Pacific region. Notably, there is evidence that the most severe cases from these epidemic outbreaks are associated with neurological disorders with CNS involvement caused by EV71 infection. Because of these EV71 infection-related public health issues, the research and development of EV71 vaccine candidates have been heavily promoted. Recently, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, including inactivated vaccine, attenuated vaccine, subunit vaccine, DNA vaccine, epitope peptide vaccine, virus-like particles (VLPs). Basing on the previous studies of elicited protection in mice and rhesus monkeys, a formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been licensed by SFDA in China, Dec. 2010. The phase I clinical and phase II trials were completed, in Guangxi Province, China. The results of these clinical trials showed that this vaccine was safe and could induce effective antibodies for the infants. The purpose of phase III is to evaluate the protected and efficacy of the formalin-inactivated EV71 vaccine in Chinese infants and children (from 6 to 71 months old).
Conditions
- The Efficacy of Inactivated EV71 Vaccine (KMB17) Against HFMD in Chinese Children and Infants
Interventions
100U/0.5ml in 6-11 months old infantsBiological
inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
100U/0.5ml in 12-23 months old infantsBiological
inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
100U/0.5ml in 24-35 months old childrenBiological
inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
100U/0.5ml in 36-71 months old childrenBiological
inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and children (from 6 to 71 months old)Time frame: within the first 28 days after the first vaccination
- Evaluate the safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and children (from 6 to 71 months old)Time frame: at the 28 days after the second vaccination
- Evaluate the efficacy of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and children (from 6 to 71 months old)Time frame: within two years after the second vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangxi Provincial Center for Diseases Control and Prevention
Nanning, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.